Derma Sciences Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Derma Sciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013637
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Derma Sciences Inc (Derma Sciences) is a medical devices company. It focuses on advanced wound care and traditional wound care. Its advanced wound care product portfolio includes dermagran, silverseal, alginate dressing, aquasite hydrogel, primacol hydrocolloid, hydrocell foam and primaderm wound cleanser. The company’s traditional wound care products include sponges; wound dressings; packing; island and barrier border gauze; non-adherent impregnated; conforming bandages; elastic net dressings; compression bandages; protective products; tapes and laparotomy sponges. It offers solutions to acute care, extended care, home health care, wound and burn care clinics and physician offices. Derma Science markets its products through direct sales force in the US and Canada. In foreign markets, its products are marketed through various licensing and distribution agreements. It has offices, manufacturing and distribution facilities in Missouri and Texas in the US, Canada, the UK and China. Derma Sciences is headquartered in Princeton, New Jersey, the US.

Derma Sciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Derma Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Derma Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 9
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Derma Sciences Acquires MEDIHONEY from Comvita 11
Partnerships 12
Derma Sciences Plans To Enter Into Agreement For DSC127 12
Licensing Agreements 13
Derma Sciences Enters Into Licensing Agreement With BioD For Amniotic Membrane Wound Care Products 13
Equity Offering 15
Derma Sciences Raises USD2.3 Million in Private Placement of Shares 15
Derma Sciences Completes Public Offering Of Shares For US$86.3 Million 16
Derma Sciences Completes Public Offering Of Shares For US$36 Million 18
Derma Sciences Completes Private Placement Of Common Stock For US$20 Million 20
Derma Sciences Completes Private Placement For US$29 Million 22
Asset Transactions 24
Dukal Acquires First Aid Division from Derma Sciences for USD12.4 Million 24
Acquisition 25
Integra LifeSciences to Acquire Derma Sciences in Tender Offer 25
Derma Sciences Acquires BioD 27
Derma Sciences Acquires 7.3% Stake In Comvita For US$7 Million 29
Derma Sciences Inc – Key Competitors 30
Derma Sciences Inc – Key Employees 31
Derma Sciences Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 10, 2016: Derma Sciences Reports 2016 Third Quarter Financial Results 33
Aug 09, 2016: Derma Sciences Reports 2016 Second Quarter Financial Results 35
May 11, 2016: Derma Sciences Reports 2016 First Quarter Financial Results 37
Mar 16, 2016: Derma Sciences Reports 2015 Fourth Quarter and Full Year Financial Results 39
Jan 07, 2016: Derma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial Guidance 41
Corporate Communications 42
Aug 18, 2016: Derma Sciences Names Russell Olsen President of Advanced Wound Care 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Derma Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Derma Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Derma Sciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Derma Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 9
Derma Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Derma Sciences Acquires MEDIHONEY from Comvita 11
Derma Sciences Plans To Enter Into Agreement For DSC127 12
Derma Sciences Enters Into Licensing Agreement With BioD For Amniotic Membrane Wound Care Products 13
Derma Sciences Raises USD2.3 Million in Private Placement of Shares 15
Derma Sciences Completes Public Offering Of Shares For US$86.3 Million 16
Derma Sciences Completes Public Offering Of Shares For US$36 Million 18
Derma Sciences Completes Private Placement Of Common Stock For US$20 Million 20
Derma Sciences Completes Private Placement For US$29 Million 22
Dukal Acquires First Aid Division from Derma Sciences for USD12.4 Million 24
Integra LifeSciences to Acquire Derma Sciences in Tender Offer 25
Derma Sciences Acquires BioD 27
Derma Sciences Acquires 7.3% Stake In Comvita For US$7 Million 29
Derma Sciences Inc, Key Competitors 30
Derma Sciences Inc, Key Employees 31
Derma Sciences Inc, Subsidiaries 32

★海外企業調査レポート[Derma Sciences Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Adana Cimento Sanayii Tas
    Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report Summary Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Community Bank System Inc (CBU):企業の財務・戦略的SWOT分析
    Community Bank System Inc (CBU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Gene Techno Science Co Ltd (4584):企業の財務・戦略的SWOT分析
    Summary Gene Techno Science Co Ltd (GTS) develops and markets drug and antibodies for intractable diseases, cancer, and rare diseases. The company develops biological, biosimilar and regenerative medicine in the therapy areas of renal disease, immunological, oncology, ophthalmic, and bone related di …
  • Electricity Authority of Cyprus:企業の戦略的SWOT分析
    Electricity Authority of Cyprus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • genedrive plc (GDR)-製薬・医療分野:企業M&A・提携分析
    Summary genedrive plc (genedrive), formerly Epistem Holdings plc is a molecular diagnostics company. The company focuses on the development and commercialization of simple to use “point of need” system or point of care diagnostics platform for the diagnosis of infectious diseases and use in patient …
  • Nordex SE (NDX1):企業の財務・戦略的SWOT分析
    Nordex SE (NDX1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SOL SpA (SOL):企業の財務・戦略的SWOT分析
    Summary SOL SpA (SOL), a subsidiary of Gas and Technologies World BV, is engaged in research, produces and distributes industrial, pure, technical, and medicinal gases. The company’s technical gases include nitrogen, oxygen, hydrogen, carbon dioxide, argon, nitrous oxide, acetylene, medical gases, g …
  • Holtec International Inc:企業の戦略的SWOT分析
    Holtec International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Guangzhou Institute of Biomedicine and Health-製薬・医療分野:企業M&A・提携分析
    Summary Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that conducts research on stem cell and regenerative medicine, chemical biology, infection and immunity, public health and scientific research equipment development. The institute’s life process and disease mechanis …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Biotest AG (BIO):企業の財務・戦略的SWOT分析
    Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • IBIDEN Co Ltd (4062):企業の財務・戦略的SWOT分析
    IBIDEN Co Ltd (4062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • LHC Group Inc (LHCG):企業の財務・戦略的SWOT分析
    Summary LHC Group Inc (LHC Group) is an in-home healthcare service provider. The center offers home health, hospice, personal care services and facility-based services. It covers a range of healthcare needs for patients and families dealing with illness, injury, and chronic conditions. LHC Group pro …
  • Wellington Management Company LLP:企業の戦略・SWOT・財務情報
    Wellington Management Company LLP - Strategy, SWOT and Corporate Finance Report Summary Wellington Management Company LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Nippon Paint (China) Co Ltd:企業の戦略・SWOT・財務分析
    Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Meiji Holdings Co Ltd (2269):企業の財務・戦略的SWOT分析
    Meiji Holdings Co Ltd (2269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Diasome Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Diasome Pharmaceuticals Inc (Diasome) is a pharmaceutical company that focusses on clinical and commercial development of therapies for diabetes and obesity. The company offers products in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism. Its …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Return Energy Inc (RTN):石油・ガス:M&Aディール及び事業提携情報
    Summary Return Energy Inc (Return Energy), formerly DualEx Energy International Inc is an oil and gas company that offers oil and gas exploration and production services. The company offers services such as petroleum and natural gas exploration and production services. It operates on the Peace River …
  • CytomX Therapeutics Inc (CTMX):企業の財務・戦略的SWOT分析
    Summary CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjuga …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆